First Presentation of Systemic Lupus Erythematosus in a 24-Year-Old Male following mRNA COVID-19 Vaccine.

Case Reports in Rheumatology Pub Date : 2022-02-01 eCollection Date: 2022-01-01 DOI:10.1155/2022/9698138
Yael Raviv, Batya Betesh-Abay, Yuliya Valdman-Grinshpoun, Liora Boehm-Cohen, Michael Kassirer, Iftach Sagy
{"title":"First Presentation of Systemic Lupus Erythematosus in a 24-Year-Old Male following mRNA COVID-19 Vaccine.","authors":"Yael Raviv,&nbsp;Batya Betesh-Abay,&nbsp;Yuliya Valdman-Grinshpoun,&nbsp;Liora Boehm-Cohen,&nbsp;Michael Kassirer,&nbsp;Iftach Sagy","doi":"10.1155/2022/9698138","DOIUrl":null,"url":null,"abstract":"<p><p>The SARS-CoV-2 viral pandemic has had an immeasurable global impact, resulting in over 5 million deaths worldwide. Numerous vaccines were developed in an attempt to quell viral dissemination and reduce symptom severity among those infected. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of antinuclear autoantibodies (ANAs) with heterogenic clinical manifestations, secondary to immune complex deposition in a multitude of organ systems. There are scarcely reported cases of SLE development following COVID-19 mRNA vaccination. We present a case of a 24-year-old male without preexisting conditions or family history of autoimmune disorders, presenting with SLE following the first dose of the SARS-CoV-2 Pfizer-BioNTech mRNA vaccine.</p>","PeriodicalId":9622,"journal":{"name":"Case Reports in Rheumatology","volume":"2022 ","pages":"9698138"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825270/pdf/","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/9698138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 15

Abstract

The SARS-CoV-2 viral pandemic has had an immeasurable global impact, resulting in over 5 million deaths worldwide. Numerous vaccines were developed in an attempt to quell viral dissemination and reduce symptom severity among those infected. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of antinuclear autoantibodies (ANAs) with heterogenic clinical manifestations, secondary to immune complex deposition in a multitude of organ systems. There are scarcely reported cases of SLE development following COVID-19 mRNA vaccination. We present a case of a 24-year-old male without preexisting conditions or family history of autoimmune disorders, presenting with SLE following the first dose of the SARS-CoV-2 Pfizer-BioNTech mRNA vaccine.

Abstract Image

一位24岁男性在接种mRNA - COVID-19疫苗后首次出现系统性红斑狼疮。
SARS-CoV-2病毒大流行对全球产生了不可估量的影响,导致全球500多万人死亡。许多疫苗被开发出来,试图抑制病毒传播,减轻感染者的症状严重程度。系统性红斑狼疮(SLE)是一种以产生抗核自身抗体(ANAs)为特征的自身免疫性疾病,具有异质临床表现,继发于多种器官系统的免疫复合物沉积。接种COVID-19 mRNA疫苗后发生SLE的病例报道很少。我们报告了一例24岁男性患者,无既往病史或自身免疫性疾病家族史,在首次接种SARS-CoV-2辉瑞- biontech mRNA疫苗后出现SLE。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
35
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信